Abstract
High-risk neuroblastoma (NB) represents a problematic tumor phenotype associated with a dreary outlook. Modern molecular achievements over the last decade have seen the increase and implementation of omics technologies in oncology that promises to provide for a deeper comprehension of complex tumor pathways. The emerging concept of analyzing NB-specific omics profiles to better understand and define the behavior of advanced-stage tumors along with providing direct and targeted therapy may ultimately translate into improved outcomes for high-risk NB. Knowledge of NB proteomics has gradually become available, but the challenge remains to integrate data obtained from different levels of biological organization. In this review, we provide an overview of the proteomics-based techniques that can be used to advance and accelerate the discovery of novel molecular biomarkers for NB. By citing specific examples, we discuss how proteomics has contributed to the early detection of advanced-stage NB and minimal residual disease. We end by contemplating the emerging technologies that are likely to have a high impact on the field of NB in the near future.
Keywords: Neuroblastoma, proteomics, post-genomic era, biomarkers, minimal residual disease, metastatic tumor cells, 'omics technologies, systems biology
Current Proteomics
Title: Oncoproteomics of Neuroblastoma: A Blueprint for Future Progress
Volume: 7 Issue: 1
Author(s): Hari R. Kumar, Xiaoling Zhong, Robert J. Hickey, Linda H. Malkas and John A. Sandoval
Affiliation:
Keywords: Neuroblastoma, proteomics, post-genomic era, biomarkers, minimal residual disease, metastatic tumor cells, 'omics technologies, systems biology
Abstract: High-risk neuroblastoma (NB) represents a problematic tumor phenotype associated with a dreary outlook. Modern molecular achievements over the last decade have seen the increase and implementation of omics technologies in oncology that promises to provide for a deeper comprehension of complex tumor pathways. The emerging concept of analyzing NB-specific omics profiles to better understand and define the behavior of advanced-stage tumors along with providing direct and targeted therapy may ultimately translate into improved outcomes for high-risk NB. Knowledge of NB proteomics has gradually become available, but the challenge remains to integrate data obtained from different levels of biological organization. In this review, we provide an overview of the proteomics-based techniques that can be used to advance and accelerate the discovery of novel molecular biomarkers for NB. By citing specific examples, we discuss how proteomics has contributed to the early detection of advanced-stage NB and minimal residual disease. We end by contemplating the emerging technologies that are likely to have a high impact on the field of NB in the near future.
Export Options
About this article
Cite this article as:
Kumar R. Hari, Zhong Xiaoling, Hickey J. Robert, Malkas H. Linda and Sandoval A. John, Oncoproteomics of Neuroblastoma: A Blueprint for Future Progress, Current Proteomics 2010; 7 (1) . https://dx.doi.org/10.2174/157016410790979653
DOI https://dx.doi.org/10.2174/157016410790979653 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
Call for Papers in Thematic Issues
Mass spectrometry data acquisition and analysis for proteomics
The Thematic Issue on "Mass spectrometry data acquisition and analysis for proteomics" aims to explore the latest advancements and challenges in the field of proteomics through the lens of mass spectrometry. Proteomics, the large-scale study of proteins and their functions, plays a crucial role in understanding various biological processes and ...read more
Peptides: State-of-Art and Commercialisation Hurdles
The Editors of the Current Proteomics (CP) journal are highly privileged to welcome scientists to submit their scientific research and review articles to be considered for publication in the upcoming thematic issue. The topics should cover various aspects of peptides in regard to their synthetic methodologies, formulation approaches, pharmacological challenges, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
ras Genes and Human Cancer: Different Implications and Different Roles
Current Genomics Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer
Anti-Cancer Agents in Medicinal Chemistry Synthetic Src-Kinase Domain Inhibitors and Their Structural Requirements
Anti-Cancer Agents in Medicinal Chemistry Nephrotoxicity of Bisphenol A (BPA) -An Updated Review
Current Molecular Pharmacology Vitamins and Cognition: A Nutrigenomics Perspective
Current Nutrition & Food Science The Role of Folate-supplementation in Depression: A Narrative Review
Current Psychopharmacology Beta-Caryophyllene, a CB2R Selective Agonist, Protects Against Cognitive Impairment Caused by Neuro-inflammation and Not in Dementia Due to Ageing Induced by Mitochondrial Dysfunction
CNS & Neurological Disorders - Drug Targets Anti-cancer and Other Bioactivities of Korean Angelica gigas Nakai (AGN) and Its Major Pyranocoumarin Compounds
Anti-Cancer Agents in Medicinal Chemistry Bone Morphogenetic Protein-Smad Pathway as Drug Targets for Osteoporosis and Cancer Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Cannabinoids and Endocannabinoids in Cerebral Ischemia
Current Pharmaceutical Design SRC: Regulation, Role in Human Carcinogenesis and Pharmacological Inhibitors
Current Pharmaceutical Design Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry Prion Protein Oligomerization
Current Alzheimer Research Chemical and Bioactive Diversities of the Genus Chaetomium Secondary Metabolites
Mini-Reviews in Medicinal Chemistry Mouse Induced Glioma-Initiating Cell Models and Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Activation of Human Platelets by 2-Arachidonoylglycerol: Role of PKC in NO/cGMP Pathway Modulation
Current Neurovascular Research Yeast as a Powerful Model System for the Study of Apoptosis Regulation by Protein Kinase C Isoforms
Current Pharmaceutical Design Neuroprotective Role of Agmatine in Neurological Diseases
Current Neuropharmacology HDAC Inhibitors-New Generation of Target Specific Treatment
Mini-Reviews in Medicinal Chemistry Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Current Cancer Drug Targets